Literature DB >> 26703912

Access to Psychosocial Services Prior to Starting Antipsychotic Treatment Among Medicaid-Insured Youth.

Molly Finnerty1, Sheree Neese-Todd2, Riti Pritam3, Emily Leckman-Westin4, Scott Bilder2, Sepheen C Byron5, Sarah Hudson Scholle5, Stephen Crystal2, Mark Olfson6.   

Abstract

OBJECTIVE: To examine rates and predictors of receiving a psychosocial service before initiating antipsychotic treatment among young people in the Medicaid program.
METHOD: A retrospective new-user cohort study of 8 state Medicaid programs focused on children and adolescents 0 to 20 years, initiating antipsychotic treatment (N = 24,372). The proportion receiving a psychosocial service in the 3 months before initiating antipsychotic treatment was calculated and stratified by socio-demographic and diagnostic characteristics arranged in 9 hierarchical groups, as follows: developmental, psychotic/bipolar, disruptive, attention-deficit/hyperactivity, obsessive-compulsive, stress, major depressive, anxiety, and other disorders.
RESULTS: Less than one-half of youth received a psychosocial service before initiating antipsychotic treatment (48.8%). Compared to younger adolescents (12-17 years) initiating antipsychotic treatment (51.5%), corresponding younger children (0-5 years; 39.2%) and older adolescents (18-20 years; 40.1%), but not older children (6-11 years; 51.5%), were significantly less likely to have received a psychosocial service. In relation to youth diagnosed with psychotic or bipolar disorder (52.7%), those diagnosed with attention-deficit/hyperactivity (43.3%), developmental (41.4%), depressive (46.5%), or anxiety (35.6%) disorder were significantly less likely to have received a psychosocial service during the 3 months before antipsychotic initiation. By contrast, youth diagnosed with stress disorders (61.2%) were significantly more likely than those diagnosed with psychotic or bipolar disorders (52.7%) to have received a psychosocial service before starting an antipsychotic.
CONCLUSION: A majority of Medicaid-insured youth initiating antipsychotic treatment have not received a psychosocial service in the preceding 3 months. This service pattern highlights a critical gap in access to psychosocial services.
Copyright © 2016 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  access to care; antipsychotic treatment; children; prescribing practices; psychotherapy

Mesh:

Substances:

Year:  2015        PMID: 26703912     DOI: 10.1016/j.jaac.2015.09.020

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  10 in total

1.  Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders.

Authors:  Greta A Bushnell; Stacie B Dusetzina; Scott N Compton; Bradley N Gaynes; M Alan Brookhart; Til Stürmer
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-12-19       Impact factor: 2.576

2.  Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.

Authors:  Nella Lo Cascio; Riccardo Saba; Marta Hauser; Ditte Lammers Vernal; Aseel Al-Jadiri; Yehonatan Borenstein; Eva M Sheridan; Taishiro Kishimoto; Marco Armando; Stefano Vicari; Paolo Fiori Nastro; Paolo Girardi; Eva Gebhardt; John M Kane; Andrea Auther; Ricardo E Carrión; Barbara A Cornblatt; Benno G Schimmelmann; Frauke Schultze-Lutter; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-02-26       Impact factor: 4.785

3.  Adolescents at ultra-high risk of psychosis in Italian neuropsychiatry services: prevalence, psychopathology and transition rate.

Authors:  Lorenzo Pelizza; Silvia Azzali; Sara Garlassi; Federica Paterlini; Ilaria Scazza; Luigi Rocco Chiri; Simona Pupo; Andrea Raballo
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-10-20       Impact factor: 4.785

4.  The Complexity of Psychotropic Medication Prescription and Treating Trauma Among Youth in Foster Care: Perspectives from the Lived Experience.

Authors:  Cadence F Bowden; Cassandra Simmel; Alicia Mendez; Melanie Yu; Sheree Neese-Todd; Stephen Crystal
Journal:  Adm Policy Ment Health       Date:  2022-06-28

Review 5.  National Child Mental Health Quality Measures: Adherence Rates and Extent of Evidence for Clinical Validity.

Authors:  Bonnie T Zima; Juliet B Edgcomb; Samantha A Shugarman
Journal:  Curr Psychiatry Rep       Date:  2019-01-31       Impact factor: 5.285

6.  Adherence to Recommended Care Guidelines in the Treatment of Preschool-Age Medicaid-Enrolled Children With a Diagnosis of ADHD.

Authors:  Alex Moran; Nicoleta Serban; Melissa L Danielson; Scott D Grosse; Steven P Cuffe
Journal:  Psychiatr Serv       Date:  2018-10-30       Impact factor: 3.084

7.  Designing Safer Use of Antipsychotics Among Youths: A Human-Centered Approach to an Algorithm-Based Solution.

Authors:  Andrea L Hartzler; James D Ralston; Terry A Hannan; Kelly J Kelleher; Robert B Penfold
Journal:  Psychiatr Serv       Date:  2019-07-16       Impact factor: 3.084

8.  Treatment Patterns and Costs Among Children Aged 2 to 17 Years With ADHD in New York State Medicaid in 2013.

Authors:  Liqiong Guo; Melissa Danielson; Lindsay Cogan; Leah Hines; Brian Armour
Journal:  J Atten Disord       Date:  2018-12-14       Impact factor: 3.256

9.  Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol.

Authors:  Robert B Penfold; Ella E Thompson; Robert J Hilt; Kelly J Kelleher; Nadine Schwartz; Arne Beck; Gregory N Clarke; James D Ralston; Andrea L Hartzler; R Yates Coley; Mary Akosile; Benedetto Vitiello; Gregory E Simon
Journal:  Contemp Clin Trials       Date:  2020-10-20       Impact factor: 2.226

10.  Trends in Antipsychotic Medication Use in Young Privately Insured Children.

Authors:  Greta A Bushnell; Stephen Crystal; Mark Olfson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2020-10-20       Impact factor: 13.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.